Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

Author： Giles F.J.   Feldman E.J.   Roboz G.J.   Larson R.A.   Mamus S.W.   Cortes J.E.   Verstovsek S.   Faderl S.   Talpaz M.   Beran M.   Albitar M.   O'Brien S.M.   Kantarjian H.M.  

Publisher： Elsevier

ISSN： 0145-2126

Source： Leukemia Research, Vol.27, Iss.12, 2003-12, pp. : 1091-1096

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib

By Koh Youngil   Kim Inho   Yoon Sung-Soo   Kim Byoung   Kim Dae-Young   Lee Je-Hwan   Lee Kyoo-Hyung   Park Eunkyung   Kim Hyeoung-Joon   Sohn Sang   Joo Young   Kim Seok   Chung Jooseop   Shin Ho-Jin   Kim Sung-Hyun   Kim Chul   Song Hong   Kim Min   Hyun Myung   Ahn Jin   Jung Chul   Park Seonyang  

Annals of Hematology, Vol. 89, Iss. 7, 2010-07 ,pp. : 725-731

Springer Publishing Company

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

By La Rosee P.   Johnson K.   O'Dwyer M.E.   Druker B.J.  

Experimental Hematology, Vol. 30, Iss. 7, 2002-07 ,pp. : 729-737

Elsevier

Access to resources Recommend Favorite

Novel therapies for chronic myelogenous leukemia

By Jahagirdar B.N.   Miller J.S.   Shet A.   Verfaillie C.M.  

Experimental Hematology, Vol. 29, Iss. 5, 2001-05 ,pp. : 543-556

Elsevier

Access to resources Recommend Favorite

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

By Carella Angelo   Lerma Enrica  

Annals of Hematology, Vol. 86, Iss. 10, 2007-10 ,pp. : 749-752

Springer Publishing Company

Access to resources Recommend Favorite